Checkpoint Therapeutics, Inc. (CKPT)
NASDAQ: CKPT · Real-Time Price · USD
4.040
+0.010 (0.25%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Checkpoint Therapeutics Employees
Checkpoint Therapeutics had 23 employees as of December 31, 2023. The number of employees decreased by 1 or -4.17% compared to the previous year.
Employees
23
Change (1Y)
-1
Growth (1Y)
-4.17%
Revenue / Employee
$1,783
Profits / Employee
-$2,445,217
Market Cap
197.28M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CKPT News
- 2 days ago - Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 16 days ago - CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT - Business Wire
- 20 days ago - Sun Pharma to Acquire Checkpoint Therapeutics - PRNewsWire
- 3 months ago - Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval - Seeking Alpha
- 3 months ago - Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewsWire
- 4 months ago - Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date - Seeking Alpha
- 4 months ago - Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 6 months ago - Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 - GlobeNewsWire